Baltimore Orioles outfielder Jay Gibbons became the second of the four players who have reportedly been linked to the procurement of performance-enhancing drugs through pharmacies doing business on the Internet to meet with officials from Major League Baseball. The meeting occurred on Monday in New York where the Orioles are playing the Yankees. It was attended by Rob Manfred, MLB's executive vice president of labor relations and human resources, Jon Coyles, the sport's director of drug testing, Michael Weiner, general counsel of the Players Association, and Seth Levinson, one of Gibbons' agents, The Associated Press reported. "I met with Major League Baseball representatives and was happy to answer all of their questions," Gibbons said, confirming the meeting for the Baltimore Sun.
Cardinals outfielder Rick Ankiel met with MLB officials when the team was in Cincinnati last week. Blue Jays third baseman Troy Glaus and Angels center fielder Gary Matthews Jr., both reportedly ensnared in the same investigation, have yet to meet with MLB officials. All four of the names surfaced as a result of the two-year investigation by Albany, N.Y., District Attorney P. David Soares into the sale of drugs like human growth hormone, anabolic steroids and testosterone via pharmacies that do business on the Internet. Gibbons reportedly received six shipments of Genotropin (a brand name for synthetic HGH), two shipments of testosterone and two shipments of human chorionic gonadotropin between October 2003 and July 2005. The report said the drugs were procured from Signature Pharmacy in Orlando, Fla., the same outfit that supplied Ankiel and Glaus. Earlier this season, Commissioner Bud Selig threatened to suspend Yankees first baseman Jason Giambi if he didn't testify before the committee headed by former U.S. Sen. George Mitchell investigating baseball's so-called steroid era. The directive came after Giambi made comments about his own steroid use in USA Today. Giambi talked to Mitchell with the proviso that he didn't have to testify about drug use by other players. Selig ultimately declined to suspend Giambi after he became the only active player to appear before Mitchell's committee, which is expected to issue its report by the end of year. No word has come from the Commissioner yet whether these four players would be asked to testify before the committee.
Barry M. Bloom is a national reporter for MLB.com. MLB reporter Matthew Leach contributed. This story was not subject to the approval of Major League Baseball or its clubs.